February 4, 2021
While the unprecedented challenges presented throughout 2020 have undoubtedly changed us all, we would like to take a moment to recognize the outstanding feats our team still managed to accomplish.
January 14, 2021
Press Release issued Jan 13, 2021: Frontida BioPharm, Inc. announced today the launch of its new Category 1 (CAT.ONETM) in vitro testing and evaluation services to support the development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.
Frontida BioPharm, Inc. has Been Recognized as a Minority Owned Contract Development and Manufacturing Organization
December 14, 2020
This recognition from the NMSDC & EMSDC represents Frontida’s work to create and maintain jobs, among other processes. The NMSDC helps certified businesses find new opportunities and avenues for growth, making the future of Frontida even more exciting.
December 4, 2020
Puneet Sapra joins Frontida with the goal of accelerating corporate growth in his position as CFO. His experience in the industry, gained at some of the most influential and well-known companies in the healthcare industry, will help Frontida optimize our growth strategies. The team is excited to begin working with Mr. Sapra and participate in the processes he will lead.
December 1, 2020
Praful Agrawala joins Frontida to bolster and lead our new technology and product development efforts. His know-how gained from leading product development and launch efforts at innovative pharmaceutical companies, coupled with wide-ranging pharmaceutics knowledge will help Frontida continue to innovate and implement new manufacturing technologies.
October 29, 2020
Steven Roese has an extensive background with important and relevant experience and will work to bolster Frontida’s operational workflow. With his impressive history in the industry, Frontida is excited for Mr. Roese to confidently step into his responsibilities and be a leader within the company.
September 23, 2020
Featured Guest Speaker Wenyong Wang, PhD. 13th Portfolio Management & Pipeline Optimization for Generics Conference. October 1st, 2020 at 2:15pm (EST) on Marcus Evans Live+
Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities
August 19, 2020
Highly potent compounds serve an increasingly significant role in numerous R&D landscapes and pharmaceutical intensive medical treatments; i.e. oncology, atrial fibrillation, osteoporosis.
Fail to load posts. Try to refresh page.